Press release
Investigation announced for NYSE: NNVC shares over potential Wrongdoing at NanoViricides, Inc.
An investigation on behalf of investors in NanoViricides, Inc. (NYSE: NNVC) shares over potential wrongdoing at NanoViricides, Inc
Investors who purchased shares of NanoViricides, Inc. (NYSE: NNVC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain NanoViricides, Inc. (NYSE: NNVC officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Shelton, CT based NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections.
Shares of NanoViricides, Inc. (NYSE: NNVC) spiked from under $2 per share in mid December 2019 to $17.77 per share on January 27, , respectively to as high as $19.20 per share on January 31, 2020, and declined to as low as $4.60 per share. On March 25, 2020.
On July 23, 2020, NYSE: NNVC shares closed at $6.64 per share.
Those who purchased shares of NanoViricides, Inc. (NYSE: NNVC) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for NYSE: NNVC shares over potential Wrongdoing at NanoViricides, Inc. here
News-ID: 2153028 • Views: …
More Releases from Shareholders Foundation
Ardent Health, Inc. (NYSE: ARDT) Investor Alert: Deadline in Lawsuit on March 09 …
A deadline is coming up on March 09, 2026 in the lawsuit filed for certain investors of Ardent Health, Inc. (NYSE: ARDT) over alleged securities laws violations by Ardent Health, Inc.
Investors who purchased shares of Ardent Health, Inc. (NYSE: ARDT) have certain options and there are strict and short deadlines running. Deadline: March 09, 2026. Ardent Health, Inc. (NYSE: ARDT) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Sina Corporation (formerly NASDAQ: SINA) Investor Alert: Investigation of potent …
An investigation on behalf of investors in shares of Sina Corporation (formerly NASDAQ: SINA) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors inSina Corporation (formerly NASDAQ: SINA shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for investors in Sina Corporation (formerly NASDAQ:…
Lawsuit DEADLINE Alert: Investors who lost money with Stride, Inc. (NYSE: LRN) s …
An investor, who purchased shares of Stride, Inc. (NYSE: LRN), filed a lawsuit over alleged violations of Federal Securities Laws by Stride, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Stride, Inc. (NYSE: LRN) have certain options and for certain investors are short and strict deadlines running. Deadline: January 12, 2026. NYSE: LRN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
More Releases for NanoViricides
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNC …
"NV-387, as an effective drug would be an important tool to fight Measles resurgence in the USA and worldwide, when approved," said Anil R. Diwan, PhD, adding, "Treating a patient and providing the drug prophylactically to contacts would eliminate the need for quarantine and loss of valuable school time. An Orphan Drug Designation would help us tremendously in the mission of regulatory development and approval of NV-387 to treat Measles."
In…
NanoViricides Reports NV-387's Anti-Inflammatory Effects Could Combat Viral-Indu …
NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place," said Anil R. Diwan, Ph.D., President and Chairman, adding, "NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on…
NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotec …
NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs.
NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat viral infections-potentially creating the first "empiric antiviral therapy"…
NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapie …
Image: https://www.abnewswire.com/uploads/a4a9423b7b554d4361ce634b254d58fe.jpg
NanoViricides, Inc., a clinical-stage biotechnology company, is revolutionizing the fight against viral diseases with its proprietary nanomedicine platform. At the forefront of their research is NV-387, a broad-spectrum antiviral drug that promises to address a wide range of critical viral infections, including COVID-19, respiratory syncytial virus (RSV), influenza, and Mpox/smallpox. This innovative solution underscores NanoViricides' commitment to advancing antiviral therapies and meeting significant unmet medical needs globally.
NV-387: A Disruptive…
Nanomedicines Market Prediction and Analysis Offered By New Study | Abbott, GE H …
The primary goal of the Nanomedicines Market report is to provide readers with a low-cost understanding of the industry that has been examined utilising primary and secondary research methods. This Nanomedicines Market report's primary goal is to provide a comprehensive overview and strategic analysis of the parent industry. The research comprehensively analyses each segment as well as any associated sub-segments that are present in the market. By analysing the market's…
Ebola Treatment Market Projected to Show Strong Growth | GlaxoSmithKline, NanoVi …
HTF MI Analyst have added a new research study on Title Ebola Treatment Market - Global Outlook and Forecast 2021-2027 with detailed information of Product Types [Vaccine (Under Trials) & Drugs (Under Trials)], Applications [Hospitals, Ambulatory Surgery Centres, Specialized Clinics & Army Camps (Veteran Facilities)] & Key Players Such as Arbutus Biopharma, GlaxoSmithKline, Johnson & Johnson Services, Hemispherx Biopharma, BioCryst Pharmaceuticals, NanoViricides, NewLink Genetics, Chimerix, Sarepta Therapeutics & Mapp Biopharmaceutical…
